MedTrace Logo

Utility of CAML as Diagnostic for Early Stage Lung Cancer

NCT03992183 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-03-04

No results posted yet for this study

Summary

Primary Objective Determine the prevalence of CAMLS in patients with pulmonary nodules.

Secondary Objectives Determine the positive and negative predictive value of CAMLS in patients with pulmonary nodules who undergo biopsy.

Model combinations of clinical factors with the presence/absence of CAMLS to refine strategies for assessment of patients with pulmonary nodules. Evaluate whether these measures result in enhanced T-cell activity and/or NK cell function and number

Conditions

  • Pulmonary Nodule, Multiple
  • Pulmonary Nodule, Solitary

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Creatv Microtech, Inc.

    collaborator OTHER

  • Fox Chase Cancer Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-21
Primary Completion
2022-11-14
Completion
2022-11-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03992183 on ClinicalTrials.gov